Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other Non-Current Assets (2021 - 2025)

Summit Therapeutics' Other Non-Current Assets history spans 5 years, with the latest figure at $7.0 million for Q3 2025.

  • For Q3 2025, Other Non-Current Assets rose 277.56% year-over-year to $7.0 million; the TTM value through Sep 2025 reached $7.0 million, up 277.56%, while the annual FY2024 figure was $2.5 million, 41.05% down from the prior year.
  • Other Non-Current Assets reached $7.0 million in Q3 2025 per SMMT's latest filing, up from $6.5 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $7.0 million in Q3 2025 to a low of $140000.0 in Q3 2022.
  • Average Other Non-Current Assets over 5 years is $2.3 million, with a median of $1.9 million recorded in 2024.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 2994.29% in 2023, then tumbled 56.99% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $170000.0 in 2021, then skyrocketed by 239.41% to $577000.0 in 2022, then soared by 649.05% to $4.3 million in 2023, then crashed by 41.05% to $2.5 million in 2024, then skyrocketed by 176.06% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Other Non-Current Assets are $7.0 million (Q3 2025), $6.5 million (Q2 2025), and $4.1 million (Q1 2025).